Andrea C. King to Smoking Cessation
This is a "connection" page, showing publications Andrea C. King has written about Smoking Cessation.
Connection Strength
6.475
-
Evaluation of a Randomized Clinical Trial Comparing the Effectiveness of a Culturally Targeted and Nontargeted Smoking Cessation Intervention for Lesbian, Gay, Bisexual, and Transgender Smokers. Nicotine Tob Res. 2019 10 26; 21(11):1506-1516.
Score: 0.555
-
A pilot study of Counsel to Quit®: Evaluating an Ask Advise Refer (AAR)-based tobacco cessation training for medical and mental healthcare providers. J Subst Abuse Treat. 2019 04; 99:163-170.
Score: 0.528
-
Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial. Alcohol Alcohol. 2019 Jan 09; 54(5):559-565.
Score: 0.525
-
POINT: Are Advanced Practice Professionals More Likely to Achieve Better Tobacco Cessation Results than Physicians? Yes. Chest. 2017 09; 152(3):466-469.
Score: 0.466
-
A Qualitative Study of the Barriers to and Facilitators of Smoking Cessation Among Lesbian, Gay, Bisexual, and Transgender Smokers Who Are Interested in Quitting. LGBT Health. 2017 02; 4(1):24-33.
Score: 0.457
-
Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial. Pharmacogenet Genomics. 2015 Jun; 25(6):305-12.
Score: 0.409
-
Feasibility and effectiveness of a community-based smoking cessation intervention in a racially diverse, urban smoker cohort. Am J Public Health. 2014 Sep; 104 Suppl 4:S620-7.
Score: 0.388
-
Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial. Addiction. 2013 Oct; 108(10):1836-44.
Score: 0.359
-
Project Exhale: preliminary evaluation of a tailored smoking cessation treatment for HIV-positive African American smokers. AIDS Patient Care STDS. 2013 Jan; 27(1):22-32.
Score: 0.346
-
Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial. Biol Psychiatry. 2013 May 01; 73(9):924-30.
Score: 0.343
-
Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J Clin Psychopharmacol. 2012 Oct; 32(5):630-6.
Score: 0.340
-
Racial differences in eligibility and enrollment in a smoking cessation clinical trial. Health Psychol. 2011 Jan; 30(1):40-8.
Score: 0.301
-
Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study. Alcohol Clin Exp Res. 2009 Jun; 33(6):1044-50.
Score: 0.266
-
A pilot community-based intensive smoking cessation intervention in African Americans: feasibility, acceptability and early outcome indicators. J Natl Med Assoc. 2008 Feb; 100(2):208-17.
Score: 0.246
-
Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob Res. 2006 Oct; 8(5):671-82.
Score: 0.224
-
Naltrexone attenuates acute cigarette smoking behavior. Pharmacol Biochem Behav. 2004 Jan; 77(1):29-37.
Score: 0.185
-
Role of naltrexone in initial smoking cessation: preliminary findings. Alcohol Clin Exp Res. 2002 Dec; 26(12):1942-4.
Score: 0.172
-
Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking. Alcohol Clin Exp Res. 2014 Oct; 38(10):2622-9.
Score: 0.098
-
Race and sex associations to weight concerns among urban African American and Caucasian smokers. Addict Behav. 2011 Jan-Feb; 36(1-2):14-7.
Score: 0.073
-
Effect of clinician advice and patient preparedness to quit on subsequent quit attempts in hospitalized smokers. J Hosp Med. 2010 Jan; 5(1):26-32.
Score: 0.070
-
Development of a culturally targeted smoking cessation intervention for African American smokers. J Community Health. 2009 Dec; 34(6):480-92.
Score: 0.070
-
Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol Biochem Behav. 2000 Jul; 66(3):563-72.
Score: 0.036
-
Smoking and inflammatory bowel disease: trends in familial and sporadic cohorts. Inflamm Bowel Dis. 2007 May; 13(5):573-9.
Score: 0.015